petosemtamab (MCLA-158)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+)
Key Facts
About Merus
Merus is a Netherlands-based biotech company, founded in 2003, that develops multispecific antibody therapies for cancer. Its core technology, the Multiclonics® platform, generates bispecific (Biclonics®) and trispecific (Triclonics®) antibodies with drug-like properties. The company's pipeline is led by petosemtamab, a bispecific antibody in Phase 3 trials for head and neck cancer, and it has recently become part of Genmab, indicating a significant strategic transition.
View full company profileAbout Merus
Merus is a Netherlands-based biotech company, founded in 2003, that develops multispecific antibody therapies for cancer. Its core technology, the Multiclonics® platform, generates bispecific (Biclonics®) and trispecific (Triclonics®) antibodies with drug-like properties. The company's pipeline is led by petosemtamab, a bispecific antibody in Phase 3 trials for head and neck cancer, and it has recently become part of Genmab, indicating a significant strategic transition.
View full company profileAbout Merus
Merus is a Netherlands-based biotech company, founded in 2003, that develops multispecific antibody therapies for cancer. Its core technology, the Multiclonics® platform, generates bispecific (Biclonics®) and trispecific (Triclonics®) antibodies with drug-like properties. The company's pipeline is led by petosemtamab, a bispecific antibody in Phase 3 trials for head and neck cancer, and it has recently become part of Genmab, indicating a significant strategic transition.
View full company profile